AltaThera Pharmaceuticals LLC
$230.3K 791 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Acclarent, Inc
Acclarent, Inc reported $231,979.42 across General Payments, Research, and Ownership to 1,119 physicians and teaching hospitals across 1,119 transactions.
- $232.0K Above-median payer
- All-tracks total
- 1,119 Above-median volume
- Transactions
- 1,119 Above-median reach
- Recipients
- −$323.8K
- General Payments vs PY2023
Acclarent, Inc reported $231,979.42 across all CMS Open Payments tracks (General + Research + Ownership) to 1,119 physicians and teaching hospitals in Program Year 2024 - ranking #963 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $231,979.42, averaging $207.31 per recipient.
Acclarent, Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
28/100
Total payments
F
12/100
Transaction volume
F
18/100
Physician reach
F
18/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer acclarent-inc Acclarent, Inc
$232.0K · #963/1,925 · 0.0% industry · PY2024
- TOT $232.0K
- RANK #963
- SHARE 0.0%
- TXN 1,119
- RCP 1,119
- CAT 5
- GEN $232.0K
- ΔGEN −$323.8K
- TOP1 14.1%
- PY 2024
Volume peers
Nearest volume peer: AltaThera Pharmaceuticals LLC ($230.3K)
Acclarent, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Acclarent, Inc's CMS-reported General Payments decreased by $323.8K (−58.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ACCLARENT, INCPY2023: ACCLARENT, INCPY2024: Acclarent, Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $555,824.95
- PY2024
- $231,979.42
What the Data Shows for Acclarent, Inc
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Acclarent, Inc that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 5-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $122.1K, accounting for 52.6% of this company's General Payments and 43 transactions.
General Payment Breakdown by Type
Acclarent, Inc made 5 types of general payments. "Consulting Fee" is the largest category at $122.1K, 52.6% of General Payments.
Acclarent, Inc reports 5 general-payment categories - the top three are Consulting Fee (52.6%), Food and Beverage (22.8%), and Travel and Lodging (21.3%). The remaining 2 categories make up 3.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Acclarent, Inc divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $122.1K | 43 | 52.6% |
| Food and Beverage | $52.9K | 905 | 22.8% |
| Travel and Lodging | $49.4K | 131 | 21.3% |
| Space Rental or Facility Fees | $7.5K | 2 | 3.2% |
| Gift | $146.30 | 38 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $89,590.99 (38.6%) of $231,979.42 in this company's General Payments records across 613 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Acclarent, Inc
The five named recipients with the highest reported General Payments from this company
- 1
Marc Richard Dean
$32,625.00 across 13 reported transactions
- 2
Dennis S Poe
$26,600.63 across 15 reported transactions
- 3
Raymond L Weiss
$11,871.46 across 9 reported transactions
- 4
Troy D Woodard
$10,828.69 across 15 reported transactions
- 5
Hao Nhu Tran
$7,665.21 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Acclarent, Inc ranks #963 of 1,925 by total payments (top 50% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,333 of 1,838 by HHI (bottom 28% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Think Surgical, Inc. : $103.4K total payments, HHI 450
- Neuronetics, Inc. : $1.1M total payments, HHI 449
- OrthoPediatrics Corp. : $2.7M total payments, HHI 449
- Rhythm Pharmaceuticals, Inc. : $177.0K total payments, HHI 449
- Linvatec Corporation : $5.3M total payments, HHI 448
- Midsouth Orthopedics Inc. : $10.7K total payments, HHI 447
- Acclarent, Inc (this company) : $232.0K total payments, HHI 447
- Pinnacle Biologics, Inc : $70.6K total payments, HHI 445
- Gentleman Orthopedic Solutions : $20.0K total payments, HHI 445
- Blue Earth Diagnostics Limited : $324.1K total payments, HHI 444
- Trilliant Surgical LLC. : $844.6K total payments, HHI 443
- Innovasis Inc : $1.1M total payments, HHI 441
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Acclarent, Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Acclarent, Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Acclarent, Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Ambu Inc.
$233.8K 3,226 recipients
Compare payment profiles
Neuromechanical Innovations, LLC
$229.6K 12 recipients
Compare payment profiles
I/O Urology Corp.
$234.3K 22 recipients
Compare payment profiles
Darby Dental Supply, LLC
$229.5K 119 recipients
Compare payment profiles
Stability Biologics, LLC
$235.6K 106 recipients
Compare payment profiles
Put this to use
Acclarent, Inc ranks #963 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Acclarent, Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.